TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06279039
Drug: Exosome liquid dressing
Normalized name: Stem-cell derived exosome vesicle products
DrugBank: Stem-cell derived exosome vesicle products (DB15743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: This study mainly adopted a randomized double-blind self-half face control method. The double-blind method was that the subjects and researchers did not know the experimental group and the control group. 38 sets of matched use sets (left and right, only the manufacturer knew the specific ingredients) were respectively applied to both sides of the cheeks of patients after Q-switched laser. The blind was unblinded after the experiment.
Study: NCT06319625
Drug: Lidocaine hydrochloride
Normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Based on the invention above, the patients in the observation group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). The percutaneous approach via the paratracheal route was used for Stellate ganglion block . The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study: NCT04964427
Drug: Methylphenidate
Normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single dose of 5-10 mg of immediate release MPH (Ritalin®) will be administered in line with NICE and AIFA (Agenzia Italiana del Farmaco) guidelines for ADHD treatment.
Study: NCT00039975
Drug: Indinavir sulfate
Normalized name: Indinavir Sulfate
DrugBank: Indinavir (DB00224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00039975
Drug: Ritonavir
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00039975
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00039975
Drug: Diltiazem HCl
Normalized name: DILTIAZEM HCL
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05015608
Drug: Savolitinib + Osimertinib
DrugBank: Osimertinib (DB09330)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subjects will receive Savolitinib orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks) until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
Study: NCT05015608
Drug: Pemetrexed + Cisplatin /Carboplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pemetrexed combined with platinumon on Day 1 of 21day cycles (every 3 weeks)
Study: NCT05752734
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
DrugBank: Neisseria meningitidis group c capsular polysaccharide diphtheria toxoid conjugate antigen (DB10799)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients not administered dexamethasone will be included in this group.~Multimodal analgesia protocol is applied to all patients undergoing bariatric surgery in our clinic. According to this protocol, patients are administered iv tenoxicam 20mg, tramadol 100mg after induction of general anesthesia, and iv morphine (0.05mg/kg/IBW) intraoperatively. Postoperative analgesia: iv paracetamol 1gr every 8 hours and iv pca of 0,4mg/ml morphine (the bolus dose is 1mg, the lock-in time of 15 minutes, the 4-hour limit is adjusted to be 40% of the calculated total dose). In cases where rescue analgesia is required (VAS score ≥3) 0.5 mg/kg tramadol is administered to patients. For postoperative nausea and vomiting prophylaxis, patients are routinely administered ondansetron 4 mg IV 20 minutes before extubation.
Study: NCT06548919
Drug: Chemotherapy Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All chemotherapy treatment regimens approved for advanced breast cancer
Study: NCT05601648
Drug: Psilocybin
Normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psilocybin (25mg tablet) plus supportive psychotherapy
Study: NCT05120895
Drug: Mevalotin
Normalized name: cefalotin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablets (starting dose 5 mg)
Study: NCT05374252
Drug: PD-1 inhibitor
Normalized name: Anti-pd-1 checkpoint inhibitor pf-06801591
DrugBank: Sasanlimab (DB18849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two cycles of concurrent PD-1 antibody sintilimab combined with mytomicin C, 5-fluorouracil and IMRT, followed by adjuvant sintilimab for six months
Study: NCT06284174
Drug: Povidone-iodine solution; chlorhexidine gluconate
DrugBank: Chlorhexidine (DB00878)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Before wound closure, each group will undergo different irrigation solutions for soaking the wound for three minutes followed by rinsing with copious saline.
Study: NCT06562738
Drug: Hetrombopag
Normalized name: Hetrombopag
DrugBank: Hetrombopag (DB16184)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hetrombopag 7.5 mg, once a day, at bedtime for up to 14 days, drug administration was stopped when PLT≥100 ×10\^9/L, and take blood routine examination weekly, drug administration was resumed when PLT \< 100 ×10\^9/L. When PLT ≤30× 10\^9/L or ≥300 ×10\^9/L, take blood routine examination every 3 days.
Study: NCT06238583
Drug: Copanlisib (Aliqopa, BAY80-6946)
Normalized name: copanlisib Injection [Aliqopa]
DrugBank: Copanlisib (DB12483)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Copanlisib is supplied as lyophilized preparation in a 6 mL injection vial. The total amount of copanlisib per vial is 60 mg. The recommended dose of copanlisib is 60 mg administered as a 1 hour intravenous (IV) infusion on Days 1, 8, and 15 of a 28-day treatment cycle on an intermittent schedule (3 weeks on and 1 week off), OR at a lower dose if dose reduction has occurred on prior treatment. Patients currently included on study protocols may continue their treatment regimen at the discretion of their healthcare provider.
Study: NCT05914454
Drug: Anakinra 100Mg/0.67Ml Inj Syringe
Normalized name: ANAKINRA 100MG/0.67ML INJ SYRINGE
DrugBank: Anakinra (DB00026)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: anakinra 100 mg per day for 14 days
Study: NCT04983407
Drug: batiraxcept
Normalized name: Batiraxcept
DrugBank: Batiraxcept (DB17522)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Batiraxcept is experimental drug
Study: NCT04983407
Drug: Nab paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab paclitaxel is active comparator
Study: NCT04983407
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Gemcitabine is active comparator
Study: NCT06072326
Drug: Sotagliflozin
Normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: 200 mg/day as a tablet
Study: NCT06072326
Drug: Ambrisentan
Normalized name: Ambrisentan
DrugBank: Ambrisentan (DB06403)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2.5 mg/day as a tablet
Study: NCT06072326
Drug: Ambrisentan and Sotagliflozin
Normalized name: sotagliflozin
DrugBank: Ambrisentan (DB06403)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2.5 mg/day Ambrisentan as a tablet in combination with 200 mg/day Sotagliflozin as a tablet
Study: NCT05924750
Drug: BL-M11D1
Normalized name: BL-1020
DrugBank: BL-1020 (DB05687)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration by intravenous infusion
Study: NCT05710471
Drug: Brolucizumab
Normalized name: Brolucizumab
DrugBank: Brolucizumab (DB14864)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal injection
Study: NCT05710471
Drug: Aflibercept
Normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravitreal injection
Study: NCT06548256
Drug: Miyarisan-BM (Clostridium Butyricum Miyairi)
Normalized name: Myorisan
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: probiotics
Study: NCT05976386
Drug: Dupilumab (SAR231893)
DrugBank: Dupilumab (DB12159)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Injection solution Subcutaneous
Study: NCT04688736
Drug: Chlorpheniramine
Normalized name: Chlorpheniramine
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: An antihistamine that reduces the natural chemical histamine in the body.
Study: NCT04492553
Drug: AndroGel
Normalized name: AndroGel
DrugBank: Testosterone (DB00624)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment indication: hypogonadism after cancer treatment. Dosage: 1-2 sachets a day. Follows standard treatment.
Study: NCT05528354
Drug: DEC
Normalized name: Andec
DrugBank: Andecaliximab (DB17564)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In the time window of 60-120 days after transplantation: DEC 5mg/m2/d for 5 consecutive days every 6 to 8 weeks with a total of 4 to 6 courses if there is no severe aGVHD (grade 3 or higher) and the donor chimerism rate of bone marrow blood (STR)\>95%.~If the MRD turns positive, DLI can be performed.
Study: NCT06004843
Drug: remimazolam
Normalized name: remimazolam
DrugBank: Remimazolam (DB12404)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: in this group,patients are treated with remimazolam and remifentanil for reduced sedation.
Study: NCT06004843
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: in this group,patients are treated with propofol and remifentanil for reduced sedation.
Study: NCT06149130
Drug: Adebrelimab
Normalized name: Adebrelimab
DrugBank: Adebrelimab (DB16412)
Approvals — FDA: no, EMA: no, PMDA: no
Description: adebrelimab:1200mg intravenously, Q3W.
Study: NCT06149130
Drug: dalpiciclib
Normalized name: Dalpiciclib
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dalpiciclib:150mg once a day for 3 weeks and stop for 1 week. Q4W.
Study: NCT00065312
Drug: naveglitazar
Normalized name: Naveglitazar
DrugBank: Naveglitazar (DB12662)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002300
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol acetate (DB00351)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06493968
Drug: oxytocin
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Uterotonics will be given in the form of an IV bolus of 10 units of oxytocin immediately with the uterine incision
Study: NCT00000661
Drug: Oxazepam
Normalized name: Oxazepam
DrugBank: Oxazepam (DB00842)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00000661
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04921735
Drug: Cisatracurium
Normalized name: Cisatracurium
DrugBank: Cisatracurium (DB00565)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.15 mg/kg based on ideal body weight calculated as height (cm) minus 105 for women and height (cm) minus 100 for men or actual body weight, whichever is lower
Study: NCT04739384
Drug: Ticagrelor 90mg
Normalized name: TICAGRELOR 90MG TAB
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 90 mg followed by Ticagrelor 60 mg
Study: NCT04739384
Drug: Ticagrelor 60 mg
Normalized name: ticagrelor 60 MG
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 60 mg followed by Ticagrelor 90 mg
Study: NCT05559489
Drug: Oral Rehydration Solution
Normalized name: terpin hydrate Oral Solution
DrugBank: Terpin hydrate (DB13163)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effectiveness- implementation study of Enteral-based resuscitation with Oral Rehydration Solution (ORS) vs standard-of-care Intravenous Fluid resuscitation for moderate-sized burn injuries in Nepal
Study: NCT05559489
Drug: Lactated Ringer
Normalized name: lactated ringers
DrugBank: COVID-19 Nucleocapsid-GM-CSF Protein Lactated Ringer's Injection (DB15845)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-of-care Intravenous Fluid resuscitation
Study: NCT06064331
Drug: Lignocaine
Normalized name: Lignocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV bolus of 1.5 mg/kg of lignocaine 2% diluted in 10 ml syringe over 3 mins followed by infusion at 1 mg/kg/h of lignocaine 2% in 20 ml syringe
Study: NCT06044480
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administration of a single preoperative dose of 4 mg of dexamethasone given intravenously 30 minutes before operation.
Study: NCT05674513
Drug: Ulipristal acetate
Normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Evaluating the pharmacodynamic and pharmacokinetic outcomes after 1 dose of Ulipristal acetate 30mg in individuals with and without active CYP3A5 alleles
Study: NCT05773001
Drug: Ozone
Normalized name: OZONE
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will perform alternating 15 minutes rest with 15 minutes treadmill walk exercise periods for 135 minutes in while breathing Ozone (O3).
Study: NCT05948683
Drug: MDMA
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The stimulant MDMA
Study: NCT06323239
Drug: Toripalimab
Normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 cycles for combined therapy. Toripalimab maintenance for 1 year.
Study: NCT06323239
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6 cycles for combined therapy.
Study: NCT06323239
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6 cycles for combined therapy.
Study: NCT04840602
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT04840602
Drug: Venetoclax
Normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT05046860
Drug: Dalbavancin
Normalized name: Dalbavancin
DrugBank: Dalbavancin (DB06219)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The unit dose of dalbavancin administered via the peripheral venous route will be 1500 mg at each injection with a first injection at Day1, a second injection at Day15 and a third at Day36, which corresponds to 61 days of treatment with dalbavancin.~In case of residual dalbavancin dosage at Day15 lower than 15 mg/L (rare situation) and a minimal inhibitory concentration for dalbavancin of 0.125mg/L (less than 5% of the strains), an injection every 14 days will be necessary, i.e. Day1, Day15, Day29, Day43 and Day57, which corresponds to 71 days of dalbavancin treatment.~Rifampicin should be given orally at a dose of 600 mg on an empty stomach in the morning for patients weighing less than 70 kg and 900 mg on an empty stomach in the morning for patients weighing more than 70 kg.
Study: NCT05358756
Drug: EDURANT 25Mg Tablet
Normalized name: EDURANT 25mg Tablet
DrugBank: Rilpivirine (DB08864)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single administartion of six EDURANT 25mg tablets (Total 150mg)
Study: NCT05563948
Drug: Cannabis
Normalized name: Cannabis
DrugBank: Medical Cannabis (DB14009)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaporized cannabis will be administered 3x/day for 15 days.
Study: NCT06470256
Drug: Durvalumab
Normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Starting two weeks post-surgery, patients began intravenous infusions of the PD-L1 monoclonal antibody, Durvalumab.
Study: NCT06470256
Drug: Lenvatinib
Normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Three weeks post-surgery, patients commenced oral administration of Lenvatinib.
Study: NCT05514314
Drug: Icotinib
Normalized name: icotinib
DrugBank: Icotinib (DB11737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Within 4-6 weeks after surgery, Icotinib 125mg orally, TID was started for 2 years, or treatment was discontinued due to tumor recurrence or intolerance
Study: NCT05074472
Drug: ZB131
Normalized name: ZB131
DrugBank: ZB131 (DB17164)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZB131 will be administered once weekly by intravenous infusion with the weight at baseline used for mg/kg dose calculations.
Study: NCT05326984
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin will be administered orally to the experimental group by randomization at a dose of 1000mgm2 per day, with maximum dose of 850mg three times a day, from day -7 to the end of the remission induction period.
Study: NCT06062277
Drug: Colchicine 0.5 MG
Normalized name: colchicine 0.5 MG
DrugBank: Colchicine (DB01394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one oral tablet daily for 30 days
Study: NCT05576389
Drug: Camrelizumab+Fluzoparib
Normalized name: Ocrelizumab
DrugBank: Camrelizumab (DB14776)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Fluzoparib：150mg was given orally twice daily Camrelizumab：200 mg IV drip on Day 1 of each cycle
Study: NCT05338047
Drug: Pegfilgrastim
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Single 6mg dose of generic pegfilgrastim or brand name pegfilgrastim, at day +1 after autotransplant.
Study: NCT04966546
Drug: Memantine Hydrochloride
Normalized name: Memantine Hydrochloride
DrugBank: Memantine (DB01043)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Active drug arm
Study: NCT05977907
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab is an investigational drug in this study
Study: NCT05505162
Drug: Zibotentan
Normalized name: Zibotentan
DrugBank: Zibotentan (DB06629)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive two capsules of Zibotentan orally QD from day 6-19.
Study: NCT05913570
Drug: Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody
DrugBank: Cadonilimab (DB16680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg/kg, Q3W for 4 cycles
Study: NCT06427200
Drug: Lactoferrin
Normalized name: Lactoferrin
DrugBank: Lactoferrin (DB16555)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lactoferrin twice daily before meals as add-on therapy for 12 weeks.
Study: NCT06392438
Drug: CycloSPORINE Ophthalmic
Normalized name: cycloSPORINE ophthalmic
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unidose of Cequa provided without charge to the participant. 1 drop in each eye morning and evening.
Study: NCT04926051
Drug: BMS-986172
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Specified dose on specified days
Study: NCT05626998
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The participants will receive intramuscular dexmedetomidine injection (1 µg/kg) diluted in 2ml normal saline thirty minutes before surgery in the ward.
Study: NCT05626998
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The participants will receive 600 mg gabapentin (two capsules each containing 300 mg) thirty minutes before surgery in the ward
Study: NCT00002062
Drug: Spiramycin
Normalized name: spiramycin
DrugBank: Spiramycin (DB06145)
Approvals — FDA: no, EMA: no, PMDA: yes
Study: NCT05963035
Drug: 18F-PFPN
Normalized name: (18F)-Fluoride
DrugBank: Fluoride ion F-18 (DB09398)
Approvals — FDA: no, EMA: no, PMDA: no
Description: For patients clinically suspected or confirmed clear cell sarcoma of soft tissue, integrated PET/MR or PET/CT imaging will be performed using targeted melanin-specific imaging agent 18F-PFPN. Meanwhile, multiple parameters will be compared with the general imaging agent 18F-FDG.
Study: NCT06251648
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients exposed to LEN
Study: NCT05115123
Drug: Duloxetine
Normalized name: Duloxetine
DrugBank: Duloxetine (DB00476)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 mg duloxetine
Study: NCT04874948
Drug: 500mg BTZ-043 containing 3.7 MBq of [14C]BTZ-043
DrugBank: BTZ-043 (DB17737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral administration of 14C-labeled radioactive 500mg BTZ-043
Study: NCT06649942
Drug: Moxifloxacin 400 mg
Normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: moxifloxacin 400 mg tablet
Study: NCT05013385
Drug: Spesolimab
Normalized name: Spesolimab
DrugBank: Spesolimab (DB15626)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spesolimab
Study: NCT00002284
Drug: Zidovudine
Normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05275374
Drug: XP-102
Normalized name: XP-102
DrugBank: XP-102 (DB18780)
Approvals — FDA: no, EMA: no, PMDA: no
Description: XP-102 will be administered orally once or twice daily in a continuous regimen.
Study: NCT05275374
Drug: Trametinib
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Trametinib will be administered 2mg orally once a day.
Study: NCT00001135
Drug: Nevirapine
Normalized name: Nevirapine
DrugBank: Nevirapine (DB00238)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002000
Drug: Valacyclovir hydrochloride
Normalized name: Valacyclovir Hydrochloride
DrugBank: Valaciclovir (DB00577)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00002000
Drug: Acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT06279767
Drug: 6-mercaptopurine
Normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 6-mercaptopurine (6-MP) is a crucial drug in the maintenance phase of acute lymphoblastic leukemia treatment.
Study: NCT05345964
Drug: GST-HG151
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will take GST-HG151 orally(once daily) on Day 1
Study: NCT05345964
Drug: GST-HG151
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects will take GST-HG151 orally (once daily) from Day 1 to Day 7
Study: NCT05598320
Drug: TransCon CNP
Normalized name: TransCon CNP
DrugBank: ACP-015 (DB17824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-weekly subcutaneous injection of 100 µg/kg TransCon CNP
Study: NCT05345964
Drug: GST-HG151
Normalized name: camphor
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group A was administered under the fasting condition of Day1 in the first cycle, and under the postprandial conditions of Day8 \~ Day15 in the second cycle. The two cycles are cross-administered, and the cleaning period is 7 to 14 days.